1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMASIMPLE Aktie jetzt für 0€ handeln | |||||
| 14.02.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.02.2024 | 845 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 14.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.02.2024ISIN Name
BE0974429624... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,111 | -1,78 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| SYNBIOTIC | 4,240 | -6,81 % | SYNBIOTIC plant weitere Übernahmen in 2025 | Mitteilung der SYNBIOTIC SE: SYNBIOTIC mit vier neuen Beteiligungen in 2024: Weitere Übernahmen für 2025 in Sicht Die europäische Industriehanf- und Cannabis-Unternehmensgruppe SYNBIOTIC SE (ISIN DE000A3E5A59... ► Artikel lesen | |
| BIONANO GENOMICS | 5,870 | -26,05 % | Bionano Genomics: Bionano Announces Effective Date of Reverse Stock Split | SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 99,10 | +0,85 % | Axsome Therapeutics stock hits 52-week high at $105.18 | ||
| JAGUAR HEALTH | 0,879 | +3,33 % | Jaguar Health, Inc.: Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease , with Proof-of-Concept Data Potentially Available H1 2025 | Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab EmiratesPOC data generated from this study could potentially lead to reimbursed early patient access... ► Artikel lesen | |
| TRULIEVE CANNABIS | 4,560 | -3,55 % | Trulieve to Open Medical Cannabis Dispensary in Palm Coast, Florida | ||
| ENDO | - | - | Endo, Inc.: Endo Launches New Peyronie's Disease Campaign: I Got Somebody | Disease awareness campaign encourages men to overcome their embarrassment and openly discuss Peyronie's disease (PD), taking charge of their health.Campaign empowers men to connect with trusted... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 327,80 | -0,27 % | What You Need to Know Ahead of West Pharmaceutical Services' Earnings Release | ||
| SHIONOGI | 14,400 | +3,60 % | Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan | QUVIVIQ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024... ► Artikel lesen | |
| KALA BIO | 7,505 | -2,41 % | KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock | ||
| HERITAGE CANNABIS | 0,001 | 0,00 % | Heritage Cannabis Holdings Corp.: Heritage Cannabis Announces Completion of Sale and Delisting from the CSE and the OTCQX | TORONTO, Aug. 29, 2024 /CNW/ - Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) ("Heritage" or the "Company") today announces, that, in connection with its creditor protection proceedings... ► Artikel lesen | |
| THERIVA BIOLOGICS | 1,400 | -4,11 % | Theriva Biologics, Inc. - S-1/A, General form for registration of securities | ||
| CHARLOTTES WEB | 0,087 | +1,75 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports 2024 Third quarter Financial Results | Sequential quarterly growth returns for 2024 New Product Innovations Driving Omni-Channel Expansion
LOUISVILLE, Colo., Nov. 14, 2024 /PRNewswire/ - (TSX: CWEB... ► Artikel lesen | |
| BEXIMCO | 0,424 | 0,00 % | Beximco faces scrutiny over loans linked to 16 non-existent factories | ||
| LUYE PHARMA | 0,256 | +2,40 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA |
Das Unternehmen PHARMASIMPLE SA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMASIMPLE SA finden Sie auf Wallstreet Online.
